Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT00248079 | The Medtronic RESOLUTE Clinical Trial | PHASE1 | COMPLETED | 139 | — | — | Nov 1, 2005 | Oct 1, 2011 | Oct 20, 2011 | 1 | Australia |
| Name | Type | Description |
|---|---|---|
| Coronary Artery Stenting | DEVICE | Initial implant of drug eluting stent (zotarolimus) |
Inclusion Criteria: 1. Patient is at least 18 years old 2. Patient is an acceptable candidate for percutaneous coronary intervention and emergent coronary artery bypass graft surgery 3. Patient has clinical evidence of ischemic heart disease or a positive functional study 4. Female patients of chil...